drugset / Trial / NCT05674994

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

NCT05674994

Phase 3 Recruiting 110 enrolled Fondation Hôpital Saint-Joseph
RandomizedParallel-groupDouble-blindTreatment

Summary

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate the improvement of the prognosis of EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.

Timeline

Start
2023-10-26
Primary completion
2026-03-30
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 10 mg/kg Intravenous
Subject Prednisone Other / unclassified 10 mg Oral